Susquehanna International Group’s Titan Pharmaceuticals TTNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-980
Closed -$8.08K 13354
2023
Q4
$8.08K Sell
980
-2,127
-68% -$15.8K ﹤0.01% 12089
2023
Q3
$28.9K Buy
+3,107
New +$33.3K ﹤0.01% 11503
2022
Q1
Sell
-1,947
Closed -$40.4K 13994
2021
Q4
$40K Buy
+1,947
New +$58.7K ﹤0.01% 12662
2020
Q2
Sell
-1,445
Closed -$249K 10954
2020
Q1
$202K Buy
1,445
+530
+58% +$82.8K ﹤0.01% 8677
2019
Q4
$107K Buy
+915
New +$110K ﹤0.01% 9115
2019
Q3
Sell
-82
Closed -$37K 10871
2019
Q2
$63K Buy
+82
New +$74.9K ﹤0.01% 9783
2019
Q1
Sell
-21
Closed -$20.4K 9868
2018
Q4
$17K Buy
+21
New +$23.5K ﹤0.01% 8700
2018
Q2
Sell
-21
Closed -$80K 10447
2018
Q1
$80K Buy
21
+18
+600% +$75.3K ﹤0.01% 8789
2017
Q4
$16K Hold
3
﹤0.01% 9089
2017
Q3
$19K Sell
3
-5
-63% -$31K ﹤0.01% 8652
2017
Q2
$52K Buy
+8
New +$74.4K ﹤0.01% 8878
2017
Q1
Sell
-14
Closed -$197K 9973
2016
Q4
$203K Buy
14
+7
+100% +$118K ﹤0.01% 8630
2016
Q3
$145K Buy
+7
New +$136K ﹤0.01% 7793

Other funds holding TTNP

Susquehanna International Group's TTNP Position: Q1 2024 in Review

Susquehanna International Group sold out of Titan Pharmaceuticals (TTNP) in Q1 2024, closing a stake of 980 shares — an estimated $8.08K sold.

Susquehanna International Group first reported a position in TTNP in Q3 2016 and held it in 13 quarters. The position peaked at $203K in Q4 2016. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2024.

  • Susquehanna International Group reported no remaining Titan Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 980 Titan Pharmaceuticals shares in Q1 2024, an estimated $8.08K.
  • Susquehanna International Group first reported a position in Titan Pharmaceuticals in Q3 2016 and held it in 13 quarters.
  • Susquehanna International Group's Titan Pharmaceuticals position peaked at $203K in Q4 2016.
  • 17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.